NUCANA PLC-ADR (NCNA) Stock Price, Forecast & Analysis
NASDAQ:NCNA • US67022C3043
NCNA Key Statistics, Chart & Performance
The current stock price of NCNA is 2.24 USD. In the past month the price decreased by -24.07%. In the past year, price decreased by -99.99%.
NCNA Technical Analysis
NCNA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NCNA. The financial health of NCNA is average, but there are quite some concerns on its profitability.
NCNA Financial Highlights
Over the last trailing twelve months NCNA reported a non-GAAP Earnings per Share(EPS) of -69.05. The EPS increased by 99.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.16% | ||
| ROE | -106.15% | ||
| Debt/Equity | 0 |
NCNA Forecast & Estimates
NCNA Ownership
NCNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.63 | 403.74B | ||
| AMGN | AMGEN INC | 17.06 | 206.168B | ||
| GILD | GILEAD SCIENCES INC | 16.49 | 183.174B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.69 | 123.671B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.88 | 81.636B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.87 | 43.973B | ||
| INSM | INSMED INC | N/A | 33.829B | ||
| NTRA | NATERA INC | N/A | 29.154B | ||
| BIIB | BIOGEN INC | 12.54 | 28.637B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.16 | 20.386B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NCNA
Company Profile
NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Company Info
NUCANA PLC-ADR
Lochside House, 3 Lochside Way
Edinburgh EH12 9DT GB
CEO: Hugh Griffith
Employees: 21
Phone: 4401313571111
NUCANA PLC-ADR / NCNA FAQ
What does NUCANA PLC-ADR do?
NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
What is the stock price of NUCANA PLC-ADR today?
The current stock price of NCNA is 2.24 USD. The price increased by 4.67% in the last trading session.
What is the dividend status of NUCANA PLC-ADR?
NCNA does not pay a dividend.
How is the ChartMill rating for NUCANA PLC-ADR?
NCNA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for NCNA stock?
NUCANA PLC-ADR (NCNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-69.05).
How many employees does NUCANA PLC-ADR have?
NUCANA PLC-ADR (NCNA) currently has 21 employees.